About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NAMSA to Acquire European-Based Medanex Clinic to Expand Early-Stage Preclinical Research Capabilities

By: via Business Wire

NAMSA, a world-leading MedTech Contract Research Organization (CRO) offering global end-to-end development services, announced today its nearing acquisition of Medanex Clinic, a Belgium-based European preclinical research organization.

Founded in 2010, Medanex focuses on providing exceptional preclinical services to the medical device industry in Europe and across the globe. Their team of internationally renowned Cardiovascular surgeons and staff are well-known for guiding Clients through the preclinical study design pathway to achieve successful results. World-leading companies, as well as small innovative research groups, regularly partner with Medanex for their outstanding Cardiovascular services and timely, efficacious study outcomes.

“NAMSA is very excited to expand its European preclinical services with the addition of Medanex,” said Dr. Christophe Berthoux, CEO of NAMSA. “Their robust preclinical capabilities and expertise, specifically in the Cardiovascular arena, will help enhance the NAMSA Client experience. We are pleased to partner with an organization that strongly shares our core values and drive to accelerate medical device development throughout the world,” Dr. Berthoux concluded.

As the global leader of the medical device testing industry, NAMSA has amassed the largest breadth and depth of therapeutic expertise and knowledge than any other preclinical development partner in industry. The organization’s preclinical research services provide support for all model types, treatments and implant requirements. NAMSA also provides Clients the benefit of full continuum development services, including regulatory, reimbursement, quality and clinical research services—proven to reduce timelines up to 30 percent over industry averages.

“Medanex is proud to become a part of the NAMSA Family. With a similar vision to deliver world class expertise and exceptional service and resources to the medical device industry, we are ideally aligned. For 12 years, we’ve grown to become a trusted and respected partner for the most challenging surgical studies while remaining customer-oriented and striving for scientific excellence,” stated Medanex CEO, Hadewych Van Hauwermeiren. “With the complementary expertise and resources of NAMSA, we will serve our Clients in an even greater capacity and look forward to joining the world’s leading CRO for Cardiovascular research,” Van Hauwermeiren concluded.

The acquisition of Medanex Clinic increases NAMSA’s scale in Europe and growing global presence, now serving Clients in 20 locations across the Americas, Asia-Pacific and Europe.

The price and terms of the approaching transaction are undisclosed.

ABOUT NAMSA

Helping medical device Sponsors improve healthcare since 1967, NAMSA is the world’s leading MedTech Contract Research Organization (CRO) offering global end-to-end development services. Driven by its global regulatory expertise and in-depth therapeutic knowledge, NAMSA is dedicated to accelerating medical device product development, offering only the most proven solutions to move clients’ products through the development lifecycle efficiently and cost-effectively. From medical device testing; regulatory, reimbursement and quality consulting; and clinical research services, NAMSA is the industry’s premier, trusted partner for successful development and commercialization outcomes. Web: www.namsa.com

ABOUT Medanex

Medanex Clinic is a CRO with a passion for excellence. As such, it is committed to "raising the bar" in every aspect of preclinical research, from impeccable in-vivo studies to highly appreciated customer service and outstanding animal welfare. Medanex masters a broad range of preclinical surgical models in different disciplines. Experienced veterinary surgeons assist with or conduct a wide variety of procedures. A large network of experts in human medicine is available on consultancy basis to perform specialized surgeries. Web: http://medanex.com/

Contacts

More News

View More
SoundHound Breaks Critical Resistance: How High Can It Get Now?
Via MarketBeat
Topics Artificial Intelligence
Tickers SOUN
Klarna IPO: BNPL Stock or Something Bigger?
Via MarketBeat
Topics Artificial Intelligence Initial Public Offering
Tickers AFRM KLAR
Why Teradyne Is a Core Play in the AI Hardware Boom
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers TER
Meta Debuts Next-Gen AI Glasses—A Turning Point for Reality Labs?
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL META
How IREN is Building an AI Powerhouse on a Bitcoin Foundation
Via MarketBeat
Topics Artificial Intelligence Supply Chain
Tickers IREN NVDA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.